You are here

  • Home
  • Archive
  • Volume 72, Issue 10
  • A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Yoo DH, Hrycaj P, Miranda P, et al
A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study
Annals of the Rheumatic Diseases 2013;72:1613-1620.